Targeted Cancer Therapy Technologies

Lead product (Mab AR9.6) under development is for a novel target for cancer therapy discovered at University of Nebraska Medical Center;

  • Target: truncated O-glycans on MUC16

Second product (ACP2127) under development is for a well-established target for cancer treatment

  • Target: CDK/mTOR

Company highlights

  • Combinatorial approach for optimal efficacy
  • Diversified Product Pipeline with two proprietary technologies
  • Experienced management and scientific team
  • Access to academic and clinical expertise

Link to AmrutBio Presentation